Navigation Links
Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2008 Financial Results and Corporate Update on March 12, 2009
Date:3/5/2009

SAN DIEGO, March 5 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, today announced that it will release its fourth quarter and full year ended December 31, 2008 financial results after the market closes on Thursday, March 12, 2009.

Cadence management will host a conference call and live webcast to discuss the financial results and provide a clinical program update on Thursday, March 12, 2009 at 1:30 pm Pacific Time (4:30 pm Eastern Time). Interested investors may participate in the conference call by dialing 877-681-3371 (domestic) or 719-325-4846 (international). To access the webcast, please visit the company's website at www.cadencepharm.com and go to the Investor Relations page. A replay of the webcast will be available approximately two hours after the call and remain available on the company's website until the next quarterly financial results call.

About Cadence Pharmaceuticals, Inc.

Cadence Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting. The company currently has two Phase III product candidates in development, Acetavance(TM) (intravenous acetaminophen) for the treatment of acute pain and fever, and Omigard(TM) (omiganan pentahydrochloride 1% topical gel) for the prevention of catheter-related infections. For more information about Cadence's pipeline, visit www.cadencepharm.com.

Cadence(TM), Acetavance(TM) and Omigard(TM) are trademarks of Cadence Pharmaceuticals, Inc.

    Contacts:   William R. LaRue
                SVP & Chief Financial Officer
                Cadence Pharmaceuticals, Inc.
                858-436-1400

                Anna Gralinska
                Director, Investor Relations
                Cadence Pharmaceuticals, Inc.
                858-436-1452


'/>"/>
SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
2. Cadence Pharmaceuticals Names Malvina Laudicina Vice President of Regulatory Affairs and Quality Assurance
3. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at UBS 2007 Global Life Sciences Conference
4. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at BIO Investor Forum
5. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at BIOCOM Investor Conference 2007
6. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2007 Financial Results
7. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference on February 5, 2008 in New York
8. Cadence Pharmaceuticals to Raise up to $49.3 Million in Registered Direct Common Stock Offering
9. Cadence Pharmaceuticals Completes $49.3 Million Registered Direct Offering
10. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results and Clinical Program Overview on March 12, 2008
11. Cadence Pharmaceuticals to Present at the Cowen and Company 28th Annual Health Care Conference on March 20, 2008 in Boston
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2017)... ... June 23, 2017 , ... Ken Hanson, a medical imaging research scientist at ... been selected as this year’s recipients of two top awards from SPIE, the ... with other honorees to accept their awards at a banquet in San Diego, California, ...
(Date:6/23/2017)... IN (PRWEB) , ... June 23, 2017 , ... ... voice for model aircraft flying hobbyists, and the University Aviation Association (UAA), the ... college students. The UAS4STEM Collegiate Challenge will encourage teamwork, competition, and success through ...
(Date:6/22/2017)... ... June 21, 2017 , ... RMC Pharmaceutical Solutions, Inc. ... Timothy Reinhardt to manage the new site. , Tim has 25 years of ... most recent role as the Director of Manufacturing and Supplier Quality Assessment. ...
(Date:6/22/2017)... ... 2017 , ... AESKU.GROUP, an innovation leader in autoimmune ... GmbH, thereby expanding its product portfolio to include allergy and food intolerance diagnostics. ... eczema or a food allergy. Allergies are escalating to epidemic proportions and becoming ...
Breaking Biology Technology:
(Date:4/13/2017)... According to a new market research report "Consumer IAM Market ... Authorization), Service, Authentication Type, Deployment Mode, Vertical, and Region - Global Forecast ... from USD 14.30 Billion in 2017 to USD 31.75 Billion by 2022, ... ... MarketsandMarkets Logo ...
(Date:4/6/2017)... 6, 2017 Forecasts by Product ... Readers, by End-Use (Transportation & Logistics, Government & Public ... & Fossil Generation Facility, Nuclear Power), Industrial, Retail, Business ... Are you looking for a definitive report on ... ...
(Date:4/3/2017)... WASHINGTON , April 3, 2017 /PRNewswire-USNewswire/ ... single-cell precision engineering platform, detected a statistically ... cell product prior to treatment and objective ... highlight the potential to predict whether cancer ... prior to treatment, as well as to ...
Breaking Biology News(10 mins):